← Back

Xiamen Kingdomway Group Co

Xiamen Kingdomway Group Company manufactures and sells nutrition and health products in China and internationally. It offers dietary supplements, functional foods, and sports nutrition under brands including Doctor's Best, Zipfizz, Kingdaway, Labrada, Prosupps, Wu Kun, Viactiv, RxSugar, LeanBody, and Jinlexin. Products are sold through online platforms and supermarkets. The company was formerly known as Xiamen Jindawei Vitamin Co., Ltd., was founded in 1997, and is based in Xiamen, China.

Country
Price · split & dividend adjusted
News & notes moving 002626.CS
002626.CS

Kingdomway's first-half net profit attributable to parent falls 31.2% year on year to 170 million yuan

Kingdomway released its 2026 interim report, showing first-half net profit attributable to the parent of 170 million yuan, down 31.2% year on year. Operating revenue was 1.77 billion yuan, up 2.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 159 million yuan, down 34.0% year on year. Net operating cash flow was 261 million yuan, down 20.1% year on year. In the second quarter, operating revenue was 960 million yuan, up 6.5% year on year, and net profit attributable to the parent was 104 million yuan, down 16.8% year on year. The company said it will continue to advance key projects including the 10,000-ton oil and fat project of Inner Mongolia Kingdomway Pharmaceutical and the smart factory construction project for nutritional and health products.
财中社·25dRead more →
002626.CS

Jindawei Subsidiary Obtains Invention Patent for Pyrroloquinoline Quinone Disodium Salt Separation and Purification Method

Xiamen Jindawei Group Co., Ltd. announced that the company and its subsidiaries, Inner Mongolia Jindawei Pharmaceutical Co., Ltd. and Jindawei Biotechnology (Jiangsu) Co., Ltd., recently received one invention patent certificate issued by the National Intellectual Property Administration. The patent is titled "A Separation and Purification Method for Pyrroloquinoline Quinone Disodium Salt," with patent number ZL202510024727.1, and the grant announcement date is July 17, 2026. The patent belongs to the field of compound purification technology and can effectively improve the purity of pyrroloquinoline quinone disodium salt. The company stated that the acquisition of this patent will not have a significant impact on production and operations, but it is conducive to technological innovation and enhances core competitiveness.
Jiemian·61dRead more →
002626.CS

Jindawei Receives Two Chinese and One U.S. Invention Patents

Jindawei and its subsidiaries recently obtained two Chinese invention patents and one U.S. invention patent. The Chinese patents include a carboxylesterase mutant, its preparation method, and a method for preparing S-3-cyclohexene-1-carboxylic acid using it, as well as a sweet protein mutant, its preparation method, and applications, with both granted on June 30, 2026. The U.S. patent covers a carbonyl reductase mutant, its preparation method and applications, and a method for preparing ethyl R-6-hydroxy-8-chlorooctanoate, granted on June 23, 2026. The company stated that these patents will not have a significant impact on near-term production and operations, but will benefit technological innovation and improve the intellectual property protection system.
Jiemian·72dRead more →